Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine for Colorectal Cancer Prevention in Lynch Syndrome
2019-003011-55Phase 2Active
- Sponsor
- Karolinska Institutet
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary nonpolyposis colorectal cancer (HNPCC), colon neoplasm and colorectal cancer (CRC) comparing Mesalamine (Pentasa) arm with Placebo arm (2 arms). Primary endpoint: Occurrence of any colorectal neoplasia. Started May 2020; status: active.
02
Drugs
Salcrozine
03
Conditions
hereditary nonpolyposis colorectal cancer (HNPCC)colon neoplasmcolorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-003011-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003011-55.